Article Search

There are too many options for DLBCL now with monoclonal antibodies, bispecific and CAR-T therapy, but in frail patients, this might be an option. Tafatistamab with lenalidomide had higher ORR (55vs 50) and CR( 37 vs 27%) but this is comparing different trials, and this trial had mostly elderly pts, I do feel tafatistamab is fairly well tolerated though. But when in doubt this seems to be a fair option.

Speaking of tafatistamab, it seems it is fairly tolerable in first line with almost 75% CR added to RCHOP, adding lenolidomie 86% CR, but this is a phase 1b. Awaiting phase 3 data, we may have another first line option or may the first line option.

CAR-T for second line is better than standard of care, the question is: how about compared to BITE therapy? Future is exciting for those patients.

Pembrolizumab in lymphoma, this is not a common one, usually in young females, could be hard to treat.

5-year survival data from the Zuma trials shows that there is curative potential in r/r DLBCL with cure rates near 50%.

This is not a trial, but really a very nice review article, too. A good read especially as we may start prescribing those meds locally.